LOSCALZO JOSEPH 4
4 · IONIS PHARMACEUTICALS INC · Filed Mar 5, 2026
Insider Transaction Report
Form 4
LOSCALZO JOSEPH
Director
Transactions
- Exercise/Conversion
Common Stock
2026-03-03$38.06/sh+832$31,666→ 37,162 total - Sale
Common Stock
[F1][F2]2026-03-03$80.33/sh−832$66,833→ 36,330 total - Exercise/Conversion
Common Stock
2026-03-04$38.06/sh+200$7,612→ 36,530 total - Sale
Common Stock
[F1]2026-03-04$80.00/sh−200$16,000→ 36,330 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2026-03-03−832→ 11,168 totalExercise: $38.06From: 2023-07-01Exp: 2032-06-30→ Common Stock (832 underlying) - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2026-03-04−200→ 10,968 totalExercise: $38.06From: 2023-07-01Exp: 2032-06-30→ Common Stock (200 underlying)
Footnotes (2)
- [F1]Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 18, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.035 to $81.01 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
Signature
By: Patrick R. O'Neil, attorney-in-fact For: Joseph Loscalzo|2026-03-05